TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07880925: A Randomized, Double-blind, Parallel-arm, Comparator- and Placebo-controlled Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamic Effects, Bioavailability, Safety, and Tolerability of Trigonelline Monohydra

Sponsor: dsm-firmenich Switzerland AG · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07880925 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07880925 Rescue Dossier →